Avalyn Pharma

About:

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

Website: https://www.avalynpharma.com/

Top Investors: Andera Partners, Norwest Venture Partners, Wellington Management, F-Prime Capital, Perceptive Advisors

Description:

Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other severe respiratory diseases. Its therapies rapidly advance AP01 for the treatment of IPF, provides additional pipeline candidates for IPF, improve the care and outcomes of severe respiratory diseases, and develop novel inhaled therapeutics. Avalyn Pharma was established in 2011 and is headquartered in Seattle, Washington.

Total Funding Amount:

$273M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2011-01-01

Contact Email:

info(AT)avalynpharma.com

Founders:

Mark W. Surber

Number of Employees:

11-50

Last Funding Date:

2023-09-27

IPO Status:

Private

Industries:

© 2025 bioDAO.ai